Geron Corporation (GERN) Shares are Down -0.72%

Geron Corporation (GERN) has risen sharply, recording gains of 3.01% in the past 4 weeks. However, the stock has corrected -0.72% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 1.96% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 1.93% and the 50-Day Moving Average is 0.71%. Geron Corporation (NASDAQ:GERN): stock turned positive on Friday. Though the stock opened at $2.69, the bulls momentum made the stock top out at $2.75 level for the day. The stock recorded a low of $2.67 and closed the trading day at $2.74, in the green by 1.48%. The total traded volume for the day was 671,601. The stock had closed at $2.7 in the previous days trading.


The company Insiders own 5.82% of Geron Corporation shares according to the proxy statements. Institutional Investors own 42.48% of Geron Corporation shares.

Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.